2019 Program Agenda


www.chinatrials.com/us_boston
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am – 8:15 am</td>
<td>Main Conference Registration</td>
</tr>
</tbody>
</table>
| 8:15 am – 8:30 am | Chairperson’s Opening Remarks  
**After 11 Years, ChinaTrials Summit Comes to the US: Why Now?**  
Frank Jiang  
Chief Executive Officer  
CSTONE PHARMACEUTICALS |
| 8:30 am – 9:00 am | Knowledge Insights Presentation  
**The New Normal: US + Chinese BioPharma to Drive the Next Generation of Innovative Medicines**  
Ian Tzeng  
Managing Director  
LEK CONSULTING |
| 9:00 am – 10:00 am | Keynote Session  
**Clinical & Regulatory Overview of US + China: The Great Opportunity Emerging in the Current Landscape**  
**US:** The pressure is increasing in the US for biopharmaceutical companies to lower prices and this may bring a great opportunity for Chinese biotechs to bring their drugs to the US. The FDA has said on numerous occasions recently that they would welcome applications for approval of drugs with clinical data generated only in China, as long as high-quality level standards are met.  
**China:** In less than 24 months China has radically altered the global clinical development landscape, creating new pathways to commercialization. Since joining ICH as a full regulatory member in June 2017, the country has refocused its regulatory process on rapid approval of innovative therapies and devices, with non-Chinese biopharma firms emerging as the main beneficiaries.  
**Speakers:**  
Barbara Weber  
Chief Executive Officer  
TANGO THERAPEUTICS  
Frank Jiang  
Chief Executive Officer  
CSTONE PHARMACEUTICALS |
## Agenda & Schedule of Events

### JULY 30

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 am – 10:30 am</td>
<td>Networking Break</td>
</tr>
</tbody>
</table>
| 10:30 am – 11:00 am | Investor Perspective: Beginning With the End in Mind & Market Reaction to Clinical Data  
Bihua Chen  
Chief Executive Officer & Portfolio Manager  
CORMORANT ASSET MANAGEMENT |
| 11:00 am – 11:45 am | The Next 10 Years: How Can/Will China’s Innovation Push Dramatically Transform the Global Clinical Ecosystem for Advancing New Patient Therapies?  
Through the macro-level strategic lens, MNC Pharma’s view of China as a destination for drug development is still very much influenced by opportunities for labor arbitrage, treatment-naive patients, as well as a large population for clinical trial participation and a huge market. Over the past 10 years, a relatively short period, China's tremendous contributions to global biopharmaceutical development have not only realized these opportunities, but gone beyond to run the gamut from producing me-too, to me-better, to first-in-class therapies, while supporting innovation-based biotechnology advancement in key areas such as CAR-T, CRISPR, Big Data and A.I. In this exciting forward-looking session, we will discuss and debate what the global clinical ecosystem might look like 5-10 years from now, and what roles the US and China may both play.  
Moderator:  
Cory Williams  
Head of Phase I Unit  
PFIZER |
|                | Speakers:  
James Li  
Chief Executive Officer  
JW THERAPEUTICS  
Ryan Roller  
Director, Life Science & Healthcare  
SILICON VALLEY BANK  
Frank Jiang  
Chief Executive Officer  
CSTONE PHARMACEUTICALS  
Sean Zhang  
Chief Executive Officer  
HENGRIUI THERAPEUTICS |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| 11:45 am – 12:30 pm | **Lessons Learned from Successful Clinical Development in China by Western Biotechs** | • Attractions: Availability of subjects, speed of recruitment, patient costs, potential source of funding  
• Getting over the hump: Where to start? What questions to ask?  
• Do the benefits outweigh the complexity and management challenges  
• How to ensure quality? Can manage from outside of China  
• Using China data to support US/global registration  
**Moderator:** George Baeder  
**Senior Vice President, Strategy**  
**DMED**  
**Speakers:**  
Donnie McGrath  
Chief of Corporate Strategy & Business Development  
**BIOHAVEN PHARMACEUTICALS**  
Cory Williams  
Head of Phase I Unit  
**PFIZER**  
Qais Mekki  
Head of Clinical Science (US), Marketed Products  
**TAKEDA PHARMACEUTICALS** |
| 12:30 pm – 1:30 pm | Networking Lunch                                                       |                                               |
| 1:30 pm – 2:00 pm | **Acceptance of Clinical Data from China: A US vs. China Comparison** | Dan Zhang  
Executive Chairman  
**FOUNTAIN MEDICAL DEVELOPMENT** |
## Agenda & Schedule of Events

**JULY 30**

### 2:00 pm – 3:30 pm

**How to Navigate the Chinese Clinical and Regulatory Landscape: Challenges and Strategies for US Biotechs**

- What advice would you give to other US biotechs?
- What are the most common pitfalls companies need to be aware of and how do you avoid them?

**Workshop Leaders:**
- Min Irwin      Bin Peng      Susie Tan
- REISTONE BIOPHARMA      EPIMAB BIOOTHERAPEUTICS      HLT PHARMA

### 3:30 pm – 5:30 pm

**How to Navigate the US Clinical and Regulatory Landscape: Challenges and Strategies for Chinese Biotechs**

- How did you approach clinical development and registration in the US?
- When is the best time to start? What infrastructure do you need to have in the US to make it work? What outside resources did you use and why?
- What are the biggest surprises or challenges in seeking drug registration in the US? How did you deal with these?

**Workshop Leaders:**
- George Baeder      Joan Shen
- DMED      I-MAB BIOPHARMA
- Jules Mitchel      Eric Zhang
- TARGETHEALTH      DMED
5:30 pm – 7:30 pm

“Meet & Greet Biotechs” Networking Cocktail Reception

This early evening cocktail reception is designed to facilitate networking and introductions to all attendees of the Summit. It will feature 15 networking roundtables each hosted by up to 2 US or China-based biotechs. Any fully registered biotech company at the Summit may apply for a table; fulfilled on a first-come, first-serve basis so register early!

Use this opportunity to stop by the tables to informally meet with the CEOs/CMOs of these companies and learn more about what technologies and treatments each company is developing, make new friends and potentially begin your next partnership. These tables will be informal in nature and are designed to help promote networking between all biotech participants.

Enjoy drinks and finger foods served around while you network!
**Agenda & Schedule of Events**

**JULY 31**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8:00 am – 8:10 am | **Opening Remarks**  
Wenru Song  
President, Head of R&D / Board Director  
KIRA PHARMACEUTICALS / CAHON         |
| 8:10 am – 9:30 am | **East to West & West to East: The PI/Clinician’s Perspective on Conducting Clinical Trials in the US and China**  
Moderator:  
Wenru Song  
President, Head of R&D / Board Director  
KIRA PHARMACEUTICALS / CAHON         |

**Panelists:**
- Delong Liu  
   Professor of Medicine  
   NEW YORK MEDICAL COLLEGE / CAHON
- Zhen Su  
   Senior Vice President, Head of Global Oncology  
   EMD SERONO
- Jiping Wang  
   Associate Director, Hepatobiliary Cancer, Division of Surgical Oncology  
   BRIGHAM & WOMEN'S HOSPITAL / CAHON
- Ruirong Yuan  
   President, Chief Medical Officer / Department of Medicine  
   ADLAI NORTYE BIOPHARMA
- Lei Zheng  
   Associate Professor of Oncology  
   JOHNS HOPKINS MEDICINE / CAHON
- Tony Ho  
   Executive Vice President, Head of R&D  
   CRISPR THERAPEUTICS / CAHON
### Agenda & Schedule of Events

#### JULY 31

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Title</th>
<th>Description</th>
</tr>
</thead>
</table>
| 9:30 am – 10:15 am | **How China Can Support Global Drug Development**          | Clinical development for new and innovative new pipeline products have become more complex and competitive, particularly with pipeline products close to each other in the R&D stage. Clinical development in China has evolved for the last 15 years. This session will focus on the following areas:  
  - What are the advantage and disadvantage to include China in the global development?  
  - When is the best time to include China in the development?  
  - How to engage in China in the global development? |
|               | **Moderator:** Min Irwin                                       | REISTONE BIOPHARMA                                                         |
|               | **Speakers:**  
  Cory Williams        | PFIZER Head of Phase I Unit                                    | PFIZER                                                                     |
|               | Yaping Shou                                                  | Chief Medical Officer TRILLIUM THERAPEUTICS                                |
|               | Naiqi Ya                                                     | President EVENUS PHARMACEUTICAL LABORATORIES                               |
|               | Yong Yue                                                     | Chief Medical Officer LAEKNA THERAPEUTICS                                  |
| 10:15 am – 11:00 am | **Sailing West: How Chinese Companies Can Navigate a Changing US Clinical Trials Landscape** | With perspectives from Chinese and U.S. biotech executives, this panel will delve deep into the challenges and opportunities for Chinese companies as they build global drug development programs. The discussion will focus on U.S. FDA’s push to modernize drug R&D and how companies in the US/China can or are rethinking how they develop drugs, including, novel trial designs, the establishment of new surrogate endpoints and the sources of data used to support regulatory filings. |
|               | **Moderator:** Erin McCallister                             | BIOCENTURY                                                                |
|               |                                                              |                                                                             |
11:00 am – 11:30 am  Networking Break

11:30 am – 12:15 pm  How to File IND in Both China + US Simultaneously: Lessons Learned from Leading Chinese Biotechs
This session will bring together leading Chinese biotechs that are following a strategy to file IND in both China + US. They will share their key learnings and challenges to consider when implementing such a strategy.

- Best practices case studies when planning simultaneous trials in China + US
- Biomarkers Hurdle: shipment of samples between China + US is challenging
- Managing the risks: different medical practice, different regulatory systems

Moderator:
Bin Peng
Chief Medical Officer
EPIMAB BIOTHERAPEUTICS

Speakers:
Chris Lu  Joan Shen
Chief Executive Officer  President of R&D
LAEKNA THERAPEUTICS  I-MAB BIOPHARMA
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 pm – 1:00 pm</td>
<td><strong>Utilizing US Data for China Submission</strong></td>
</tr>
<tr>
<td>Moderator:</td>
<td>Sanjeev Redkar</td>
</tr>
<tr>
<td></td>
<td>President</td>
</tr>
<tr>
<td></td>
<td><strong>APOLLOMICS</strong></td>
</tr>
<tr>
<td>Speakers:</td>
<td>Jonathan Wang</td>
</tr>
<tr>
<td></td>
<td>Senior Vice President, Business Development</td>
</tr>
<tr>
<td></td>
<td>Minori Koshiji Rosales</td>
</tr>
<tr>
<td></td>
<td>Vice President, Clinical Development</td>
</tr>
<tr>
<td></td>
<td><strong>ZAI LAB</strong></td>
</tr>
<tr>
<td></td>
<td><strong>MACROGENICS</strong></td>
</tr>
<tr>
<td>Anna Vardanyan</td>
<td>Executive Director, BD &amp; Alliance Management</td>
</tr>
<tr>
<td></td>
<td><strong>EVEREST MEDICINES</strong></td>
</tr>
<tr>
<td>1:00 pm – 2:00 pm</td>
<td><strong>Networking Lunch &amp; ChinaTrials+US Summit Conclusion</strong></td>
</tr>
<tr>
<td>2:00 pm – 4:00 pm</td>
<td><strong>“Chinese Biotech Company Showcase” Networking Tables</strong></td>
</tr>
<tr>
<td></td>
<td>The second afternoon of the Summit will feature 10 networking</td>
</tr>
<tr>
<td></td>
<td>roundtables each hosted by a China-based biotech. Any fully</td>
</tr>
<tr>
<td></td>
<td>registered biotech company at the Summit may apply for a table;</td>
</tr>
<tr>
<td></td>
<td>fulfilled on a first-come, first-serve basis so register early!</td>
</tr>
<tr>
<td>4:00 pm</td>
<td><strong>ChinaTrials+US Summit Concludes</strong></td>
</tr>
</tbody>
</table>

For more information or to register, please visit: www.chinatrials.com/us_boston